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Olanzapine is an antipsychotic drug routinely used for 
the treatment of schizophrenia. Although the olanzap-
ine treatment is associated with disturbed electrical 
heart activity, the exact mechanism underlying this se-
vere adverse effect remains unclear. Recently, olanzap-
ine administration was demonstrated to be associated 
with elevation of blood glucose and lower levels of free 
fatty acids. Therefore, we investigated the effect of acute 
olanzapine administration on pathways regulating the 
cardiac energy metabolism in an isolated heart. Electri-
cal activity and contractile parameters were recorded in 
isolated, spontaneously beating, adult male rat hearts, 
perfused with either olanzapine (100 nmol/l) or the ve-
hicle for 10 min. Regulation of key signalling molecules 
was evaluated by immunoblotting and ATP levels were 
measured spectrophotometrically. Olanzapine prolonged 
the QTc intervals and induced a higher number of pre-
mature ventricular beats. Furthermore, olanzapine sig-
nificantly decreased the coronary flow, the rate-pressure 
product and the contractility (+dP/dt and –dP/dt). These 
changes were associated with an increased acetyl-CoA 
carboxylase phosphorylation and tissue ATP levels. We 
also found a trend for lower phosphorylation levels of 
Akt and its downstream products AS160, a key regulator 
of GLUT4 trafficking and glycogen synthase kinase-3ß 
in olanzapine-treated hearts when compared to vehicle-
treated controls. These data should contribute to the 
elucidation of mechanisms that underlie the adverse car-
diac effects of olanzapine.
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INTRODUCTION
Olanzapine belongs to the second generation of an‑
tipsychotics and is routinely used in the clinic for the 
treatment of schizophrenia. It is well known that schiz‑
ophrenic patients suffer from cardiometabolic disorders 
(Jones et al., 2013; Pasternak et al., 2014; Wang et al., 
2014), and administration of antipsychotic drugs is fol‑
lowed by higher morbidity and mortality (Jones et al., 
2013). Several adverse effects, particularly prolonged 
QT intervals, higher rates of arrhythmias (Dineen et al., 
2003; Drici et al., 1998; Gurovich et al., 2003), elevated 
risk of hyperlipidemia (Dudek et al., 2016; Horska et al., 
2016; Takeuchi et al., 2015), increased blood glucose 
and lower circulating levels of free fatty acids (Albaugh 
et al., 2012; Klingerman et al., 2014) have been reported 
after olanzapine administration. Despite the fact that 
the incidence of sudden cardiac or sudden unexpected 
death in olanzapine‑treated patients is twice as high as 
in nonusers (Salvo et al., 2016), the mechanism underly‑
ing the severe, adverse cardiac effects remains poorly 
understood.
Large amounts of energy must be generated in or‑
der to support the mechanical functions of the heart 
and disturbances in energy metabolism may be asso‑
ciated with cardiac dysfunction (Fillmore et al., 2014). 
Fatty acids and glucose are the two main sources of 
ATP in the heart. In addition to the substrate avail‑
ability and end‑product inhibition, two main signalling 
pathways regulate the cardiac energy metabolism: the 
Akt and 5’AMP‑activated protein kinase (AMPK) sig‑
nalling pathways. Under physiological conditions, Akt 
is activated by insulin or growth factors, and promotes 
glucose metabolism by stimulating translocation of the 
glucose transporters, primarily GLUT‑4 in the heart, to 
the plasma membrane. Under conditions of metabolic 
stress, the AMPK pathway is activated and promotes 
production of energy via fatty acid oxidation and phos‑
phorylation of the acetyl‑CoA carboxylase (ACC) (Fill‑
more et al., 2014; Kang et al., 2012). Importantly, in‑
creased fatty acid oxidation in the heart inhibits glucose 
utilization and is associated with a decreased oxygen 
efficiency and reduced contractile function under cer‑
tain conditions (Stanley et al., 1997). Furthermore, dys‑
regulated fatty acid metabolism may lead to lipotoxicity, 
which refers to the accumulation of toxic lipid meta‑
bolic intermediates that may lead to cellular stress and 
dysfunction, and potentially cell death (D’Souza et al., 
2016).
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Maintenance of energy homeostasis is crucial for 
preserving cellular physiology (Cieslak et al., 2016; 
Goralska et al., 2017). However, the involvement of the 
energy metabolism regulation in adverse cardiac effects 
of antipsychotics has not yet been investigated. There‑
fore, we investigated the effects of olanzapine on both, 
cardiac function and activation of key signalling mol‑
ecules that regulate the energy metabolism in the iso‑
lated heart.
METHODS
Animals. Experiments were carried out according 
to Directive 2010/63/EU and were approved by Local 
Bioethical Committees.
Experimental design and isolated heart perfu-
sions. Hearts were randomly divided into either olan‑
zapine‑ or vehicle‑ treated hearts. Isolated heart prep‑
arations were established as described below. Isolated 
hearts, after a short stabilization period (~ 15 min), 
were perfused in the unloaded (Langendorff) mode 
for five minutes, to collect baseline measurements, 
and then continuously perfused with either the vehicle 
(aqua pro injectione) or 100 nmol/l olanzapine (Zy‑
prexa, Eli Lilly; Utrecht, NLD) via the aortic cannula 
for an additional 10 minutes (Fig. 1, upper panel). Two 
series of perfusions were performed: in the first (n=5), 
the contractile function, coronary flow and ECGs were 
monitored; in the second (n=3–4), the ventricular tis‑
sue was snap‑frozen in liquid nitrogen at the end of the 
perfusion period and stored at –80°C for biochemical 
analyses.
Male, Wistar rats (230–270 g, 4–5 months) were 
maintained on a standard laboratory chow and tap wa‑
ter ad libitum. Rats were anesthetized by i.p. injection 
of 100 mg/kg ketamine and 10 mg/kg xylazine, and, 
in the first series, anticoagulated with heparin (500 IU 
i.p.). Hearts were explanted and perfused via the aorta 
at 80 mm Hg with a modified Krebs‑Henseleit solution 
(Farine et al., 2016; Knezl et al., 2017) and gassed with 
95% O2 and 5% CO2.
Functional measurements. For contractile meas‑
urements, a latex balloon was inserted into the left 
ventricle and pressure measurements were recorded 
using a LabChart 7 Pro version 7.3.7 (AD Instru‑
ments; Spechbach, Germany). Coronary effluent was 
harvested manually to determine the coronary flow 
10 minutes after vehicle or olanzapine administration. 
For electrocardiogram (ECG) recordings, needle elec‑
trodes (AD Instruments; Spechbach, Germany) were 
inserted into the left ventricle. Electrode signals were 
Figure 1. Experimental protocol and heart function.
Upper panel: Experimental protocol. Lower panels: Changes in hemodynamics after 10 min of either the vehicle (n=5, white box) or 100 
nmol/l olanzapine (n=5, grey box) administration. (A) Left ventricular systolic pressure (SP; mmHg), **p<0.01. (B) Rate pressure product 
(RPP; mmHg*BPM), *p<0.05. (C) Coronary flow (CF; ml/min), **p<0.01. (D) Maximal rates of contraction (+dP/dt; mmHg/s), *p<0.05. (E) 
Maximal rates of relaxation (–dP/dtmin; mmHg/s), *p<0.05.
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amplified with the FE136 Animal Bio Amplifier (AD 
Instruments; Spechbach, Germany) and recorded with 
a PowerLab 8/30 (AD Instruments; Spechbach, Ger‑
many). ECGs were recorded for the entire perfusion 
period.
Heart rate was calculated from the ECG recordings. 
Peak systolic pressure and their product (rate‑pressure 
product; RPP), +dP/dt and –dP/dt were calculated from 
the ventricular pressure measurements.
To evaluate ECGs, QT intervals were analyzed using 
LabChart 7 Pro version 7.3.7 (AD Instruments; Spech‑
bach, Germany). Corrected QT (QTc) was analyzed ac‑
cording to the following formula: QTc=QT/(RR/f)1/2, 
where f is the normalization factor according to the 
basal RR interval duration in rats and equals 150 ms 
(Kmecova & Klimas, 2010). To examine the effect on 
QT interval, averages of 10 consecutive beats from the 
10th minute after vehicle or olanzapine administration 
were compared. Development of ventricular arrhythmias 
was defined according to the Lambeth Convention (Cur‑
tis et al., 2013). The sum of ventricular premature beats 
(VPBs) during 10 min of vehicle or olanzapine infusion 
was compared.
Isolation of ventricular cardiomyocytes. Ventricu‑
lar cardiomyocytes were isolated as previously described 
(Ségalen et al., 2008). Briefly, isolated hearts were per‑
fused via the aortic cannula with calcium‑free Joklik’s 
medium for 10 min. Next, the heart was perfused with 
0.09% collagenase and 0.7% BSA in Joklik’s medium 
for 15 min. After the atria removal, ventricles were 
opened and incubated in an incubation buffer (10 ml 
perfusate, 8 ml Joklik’s medium, and 2 ml 10% BSA) 
for 10 min at 37°C. The heart was subsequently dis‑
sected and the suspension of cells was incubated at 
37°C for 5 min, whereas the Ca2+ concentration was 
increased every minute in steps of 200 μmol/l to 1 
mmol/l. Next, the cell suspension was filtered through 
180 µm filter mesh and centrifuged at 17×g for 1 min. 
Cells were allowed to adhere to the laminin‑coated 
plates in the HEPES‑modified medium 199 with 10% 
fetal calf serum for 1 h. Finally, cardiomyocytes were 
treated with either the vehicle (0.001 % DMSO) or 100 
nmol/l olanzapine (Sigma Aldrich, St. Louis, USA) for 
10 min.
Immunoblotting. Frozen ventricular tissue or 
ventricular cardiomyocytes were homogenized in a 
lysis buffer containing Tris‑HCl (20 mmol/l), phe‑
nylmethylsulfonyl fluoride (1 mmol/l), NaCl (137 
mmol/l), EGTA (1 mmol/l), EDTA (10 mmol/l), 
NaF (20 mmol/l), sodium pyrophosphate (1 mmol/l), 
sodium orthovanadate (1 mmol/l), glycerol (10%), 
NP‑40 (1%), aprotinin (4 μg /ml), leupeptin (4 μg/
ml), and pepstatin (4 μg/ml). Lysates were centri‑
fuged (12 000 rpm, 20 min, 4C°) and supernatants 
were stored at –80°C until use. Total protein con‑
centration of the supernatant was determined with 
the BCA protein assay kit (Pierce Biotechnology; 
Waltham, USA) according to the manufacturer’s in‑
structions. Lysates (75 μg protein) were separated 
on 7.5% SDS‑polyacrylamide gels (BioRad; Hercules, 
USA), and transferred to nitrocellulose membranes 
(Li‑COR Biosciences; Lincoln, USA). The membranes 
were blocked for 1 h with the Odyssey Blocking 
Buffer (Li‑COR Biosciences; Lincoln, USA) in PBS 
and then incubated overnight at 4°C with anti‑Akt 
(#9272, 1:1000), anti‑AS160 (#2670, 1:1000), anti‑
GSK‑3β (#sc‑9166, 1:500), anti‑ACC (#3676, 1:1000), 
anti‑IRβ (#sc‑711, 1:500), anti‑phosphoSer473‑Akt 
(#9271, 1:1000), anti‑phosphoThr642‑AS160 (#4288, 
1:1000), anti‑phosphoSer9‑GSK3β (#9323, 1:1000), 
anti‑phosphoSer79‑ACC (#11818, 1:1000). Anti‑GSK‑
3β and anti‑IRβ were purchased from Santa Cruz Bio‑
technology (Dallas, USA). All other antibodies were 
purchased from Cell Signaling Technology (Danvers, 
USA). The following day, membranes were incubated 
with anti‑mouse (Li‑COR Biosciences; Lincoln, USA) 
or anti‑rabbit (Invitrogen; Carlsbad, USA) second‑
ary antibodies (1:10 000) for 1h at room temperature. 
Bands were detected with the Odyssey NIR imaging 
system (Li‑COR Biosciences; Lincoln, USA).
ATP levels. Tissue ATP levels were determined 
spectrophotometrically as previously described (Nied‑
erberger et al., 2017). Briefly, frozen ventricular tissue 
was powdered, resuspended in perchloric acid (7%), 
homogenized in a Dounce homogenizer and neutral‑
ized with KOH‑KHCO3 (1 mol/l). 200μl of sample was 
then added to 800μl of the assay buffer containing Tris‑
HCl (60 mmol/l, pH 7.5), MgSO4 (40 mmol/l), glucose 
(2 mmol/l), nicotinamide adenine dinucleotide phos‑
phate (524 μmol/l) and glucose‑6 phosphate dehydroge‑
nase (2 U/ml). The ATP assay was initiated by adding 
hexokinase (2 U/ml) and absorbance was measured at 
340 nm. ATP levels were calculated after linear extrapo‑
lation from standard curves prepared with known quan‑
tities of ATP.
Isolation and function of the heart mitochon-
dria. Heart mitochondria were isolated as previously 
described (Misak et al., 2013). Briefly, the heart was 
disrupted with scissors and a Potter–Elvehjem homog‑
enizer with 20 strokes. Homogenate was centrifuged 
at 950×g for 5 min at 4°C. The remaining superna‑
tant was decanted to a separate tube and centrifuged at 
8 500×g for 10 min at 4°C. The pellet was resuspended 
in an isolation buffer (65 mmol/l sucrose, 225 mmol/l 
mannitol, 0.25 mmol/l EDTA, 10 mmol/l HEPES, pH 
7.4) and centrifuged at 8 500×g for 10 min at 4°C. Fi‑
nally, the pellet was resuspended in a 400 µl volume of 
isolation buffer. Total protein (mg/ml) was determined 
using the Modified Lowry Protein Assay Kit (Thermo 
Fisher, Waltham, USA). Mitochondrial preparations 
were used within 2 h. Functional parameters of isolated 
mitochondria were estimated by the Mitocell MT‑200A 
system (Strathkelvin Instruments, Scotland). Mitochon‑
dria were resuspended in a respiration buffer (120 
mmol/l KCl, 0.5 mmol/l EGTA, 3 mmol/l KH2PO, 
2% dextran, 12.5mmol/l HEPES, pH 7.4) at 30°C in 
the presence of substrates (10 mmol/l glutamate+5 
mmol/l malate) and treated with either the vehicle 
(0.001% DMSO) or 100 nmol/l olanzapine (Sigma Al‑
drich, St. Louis, USA) for 10 min. Next, 125 µmol/l 
ADP was added in order to induce state 3 (phospho‑
rylating respiration) and 100 nmol/l carbonyl cyanide 
4‑(trifluoromethoxy) phenylhydrazone (FCCP) was add‑
ed to induce state 3u (maximum uncoupler‑stimulated 
respiration). Respiration rate before and after addition 
of the vehicle, olanzapine, ADP or FCCP was calcu‑
lated as the negative slope of oxygen concentration. 
The ATP/O ratio (the relationship between ATP pro‑
duction and oxygen consumption) was calculated as the 
ratio between ADP added and the amount of oxygen 
consumed during state 3.
Data analysis and statistics. The results are present‑
ed as mean values ± S.E.M. Differences between groups 
were evaluated with t‑tests. A value of p<0.05 was con‑
sidered as significant. Analyses were performed with the 
GraphPad Prism (GraphPad Software, Inc.; San Diego, 
USA). The Shapiro‑Wilk test was used to test distribu‑
tion normality in the groups.
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RESULTS
Effects of olanzapine on cardiac function
We evaluated the effect of acute olanzapine treat‑
ment (100 nmol/l, 10 min) on contractile function and 
electrical activity of isolated rat hearts. The contractile 
function in the olanzapine‑treated hearts was depressed 
when compared to the vehicle‑treated hearts, with signif‑
icant reductions in the peak systolic pressure (p=0.007, 
Fig. 1A), rate pressure product (p=0.02, Fig. 1B), coro‑
nary flow (p=0.01, Fig. 1C), +dP/dt (p=0.03, Fig. 1D) 
and –dP/dt (p=0.03, Fig. 1E). Next, we analysed the 
effect of olanzapine on electrical activity of the hearts. 
The olanzapine treatment resulted in a significant pro‑
longation of the QT interval in comparison to the ve‑
hicle‑treated isolated hearts (p<0.0001, Fig. 2A). There 
were no significant changes between the groups in the 
heart rate (0.23, Fig. 2B). The olanzapine administra‑
tion significantly increased the QTc interval duration 
(p=0.096, Fig. 2C) and a higher incidence of ventricular 
arrhythmias was observed in olanzapine‑treated hearts 
when compared to the vehicle‑treated hearts (p=0.007, 
Fig. 2D).
Effects of olanzapine on cardiac energy state and 
pathways regulating the energy metabolism
To determine if olanzapine‑mediated cardiotoxicity is 
associated with changes in regulation of the energy me‑
tabolism of the hearts, we examined the effect of acute 
olanzapine treatment (100 nmol/l, 10 min) on the car‑
diac ATP content. Significantly higher ATP levels were 
associated with the depressed cardiac function, in olan‑
zapine‑treated hearts (p=0.046, Fig. 3A).
To investigate the mechanism by which olanzapine 
induces accumulation of ATP in the heart, we tested 
the influence of olanzapine on key regulators of fatty 
acid and glucose metabolism. ACC is a key regulator 
of fatty acid oxidation, and therefore we measured 
levels of total and phosphorylated (Ser79) ACC in the 
isolated rat hearts. Acute administration of olanzapine 
(100 nmol/l, 10 min) resulted in a significant increase 
in phosphorylation levels of ACC when compared to 
the vehicle‑treated controls (p=0.048, Fig. 3B), indi‑
cating that olanzapine deactivates ACC and thus pro‑
motes oxidation of fatty acids with subsequent ATP 
generation.
In order to investigate the mechanism by which olan‑
zapine affects the energy metabolism specifically in the 
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Figure 2. Changes in the electrical activity of the heart.
Changes in the electrical activity after 10 min of either the vehicle (n=5, white box) or 100 nmol/l olanzapine (n=5, grey box) administra‑
tion. Upper panels: Representative left ventricular pressure (LVP) and ECG recordings. Lower panels: (A) QT interval (QT), ****p<0.0001. 
(B) Heart rate (HR). (C) corrected QT interval (QTc), **p<0.01. (D) Number of ventricular premature beats (VPBs), **p<0.01.
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myocardium, we used isolated rat ventricular mitochon‑
dria and cardiomyocytes. We found a trend for higher 
ATP/O ratio after olanzapine incubation as compared 
to the vehicle treated isolated mitochondria (p=0.16, 
Fig. 4A), however, these changes were not statistically 
significant. Olanzapine did not alter the rates of basal 
respiration and the rates of maximal respiration (data 
not shown). Similarly to the whole heart, incubation 
with olanzapine (100 nmol/l, 10 min) significantly in‑
creased the level of phosphorylated ACC as compared 
to the vehicle treated isolated cardiomyocytes (p=0.03, 
Fig. 4B).
We also measured the effects of olanzapine on phos‑
phorylation of key proteins in the glucose metabolism: 
Akt kinase (Ser473), AS160 protein (Thr642; regulator of 
GLUT4 trafficking), and GSK3β (Ser9; regulator of gly‑
cogen synthesis). Acute administration of olanzapine 
appeared to decrease phosphorylation of Akt (p=0.07, 
Fig. 5A) and its downstream targets AS160 (p=0.11, 
Fig. 5B) and GSK3ß (p=0.16, Fig. 5C), however, these 
changes were not statistically significant.
DISCUSSION
Although olanzapine is one of the most prescribed 
antipsychotics for the treatment of schizophrenia, little 
is known about the molecular mechanisms of its adverse 
cardiac effects. We observed that acute olanzapine treat‑
ment was associated with a higher incidence of ventricu‑
lar arrhythmias, as well as depressed contractile function 
and coronary flow in isolated rat hearts. In addition, we 
were able to demonstrate that olanzapine increases phos‑
phorylation levels of ACC and tissue ATP levels in the 
heart, suggesting increased fatty acid oxidation. Further‑
more, we observed a lower trend for phosphorylation 
of Akt, AS160 and GSK3ß in olanzapine‑treated hearts 
when compared to the vehicle‑treated ones. These data 
indicate that acute exposure to olanzapine impairs cardi‑
ac rhythm and function in association with dysregulation 
of fatty acid metabolism in the isolated rat heart.
A higher incidence of sudden cardiac death has been 
linked to administration of antipsychotic drugs (Salvo et 
al., 2016), and QT prolongation and higher rates of ar‑
rhythmias have been reported in patients treated with 
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olanzapine (Dineen et al., 2003; Drici et al., 1998; Guo 
et al., 2009; Gurovich et al., 2003). Consistent with previ‑
ous studies, we observed a higher number of premature 
ventricular beats and an increase in the QTc interval af‑
ter acute administration of 100 nmol/l olanzapine. The 
selected dose was based on steady‑state plasma concen‑
tration of olanzapine, reaching ~ 30 ng/ml (96 nmol/l) 
with the use of 15 mg/day (Attarbaschi et al., 2007; 
Fellows et al., 2003; Mauri et al., 2005; Weigmann et al., 
2001). Blockage of hERG potassium channels results in 
increased action potential duration and represents one 
of the most common causes of QT prolongation (Re‑
canatini et al., 2005). Furthermore, inhibition of hERG 
channels has been proposed as an underlying mechanism 
of olanzapine‑induced impairment of the cardiac electri‑
cal activity (Lee et al., 2015), and response to treatment 
in schizophrenic patients is modulated by alterations in 
expression of the hERG isoforms in the brain (Apud et 
al., 2012). In addition, Morisette et al. reported that olan‑
zapine blocks the rapid component of the delayed recti‑
fier potassium current in guinea pig ventricular myocytes 
(Morissette et al., 2006). Thus, it is tempting to speculate 
that inhibition of specific potassium channels may be the 
mechanism by which olanzapine induces the prolonged 
QTc intervals following acute administration in isolated 
rat hearts.
Importantly, the observed disturbances in electri‑
cal activity of the heart after olanzapine administration 
were associated with depressed contractile function and 
reduced coronary flow. As the heart rate remained un‑
changed, decrease in the rate‑pressure product resulted 
from a significant reduction in the peak systolic pres‑
sure. These findings are consistent with those of Leung 
and colleagues, who reported that a single olanzapine 
injection significantly decreased blood pressure and left 
ventricular contraction, but did not affect the heart rate 
in rats (Leung et al., 2014). In contrast, cumulative dose 
of olanzapine induced reduction in heart rate associated 
with a decrease in the developed pressure and coronary 
perfusion pressure in an isolated guinea pig heart (Guo 
et al., 2009). The decrease in coronary perfusion pressure 
could be responsible for the reduced coronary flow and 
contractility observed in our study. Under these condi‑
tions and according to our study in the isolated heart, 
we may conclude that olanzapine mediates changes in 
the cardiac functions via local, cardiac action(s), although 
the precise underlying mechanisms remain to be deter‑
mined.
Under physiological conditions, the heart primar‑
ily uses fatty acids in order to meet its high energy de‑
mands. However, dysregulation of fatty acid metabolism 
may lead to accumulation of toxic lipid species, impaired 
myocardial contractility and arrhythmias (D’Souza et al., 
2016; Schulze et al., 2016). ACC plays a crucial role in 
regulation of fatty acid oxidation. Under conditions of 
metabolic stress, ACC is phosphorylated and deactivated 
by 5′AMP‑activated protein kinase (AMPK), thereby re‑
ducing production of the malonyl CoA and relieving its 
inhibition of carnitine palmitoyltransferase I (CPT‑I), a 
key regulator of fatty acid cytosolic‑mitochondrial traf‑
ficking. Excessive fatty acid oxidation may overwhelm 
capacity of the tricarboxylic acid cycle, thereby resulting 
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Figure 5. Influence of olanzapine perfusion on phosphorylation of Akt, AS160 and GSK3ß proteins in rat hearts.
Isolated rat hearts were perfused with either the vehicle (n=3–4, white bars) or 100 nmol/l olanzapine (n=3–4, grey bars) for 10 min. Up-
per panels: Representative western blots. Lower panels: densitometric quantification of (A) Akt phosphorylation levels (p‑Akt/IRβ vs. to‑
tal Akt/IRβ). (B) AS160 phosphorylation levels (p‑AS160/IRβ vs. total AS160/IRβ). (C) GSK‑3ß phosphorylation levels (p‑GSK‑3ß/IRβ vs. total 
GSK‑3ß/IRβ).
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in accumulation of toxic acylcarnitines (D’Souza et al., 
2016). In the present study, olanzapine treatment was 
associated with a significantly higher phosphorylation of 
ACC and elevated ATP levels in the hearts, suggesting 
increased rates of mitochondrial fatty acid oxidation. The 
observed increase in phosphorylated ACC levels was also 
present in isolated rat ventricular cardiomyocytes, sug‑
gesting that olanzapine may alter the energy metabolism 
and thereby contractile function of cardiomyocytes. In 
contrast to our study, Takami et al. showed that apripra‑
zol, but not olanzapine or other antipsychotics, increased 
phosphorylation of ACC, AMPK and intracellular ATP 
levels in PC12 cells (Takami et al., 2010). Reasons for 
these discrepant findings are unclear, but may result 
from the different models employed.
Several reports confirm that olanzapine mediated cyto‑
toxicity is associated with increased production of reac‑
tive oxygen species (ROS) (Eftekhari et al., 2016; Heiser 
et al., 2010; Martins et al., 2008; Vucicevic et al., 2014). 
We observed a trend for higher mitochondrial efficiency 
in the presence of olanzapine. Since ROS are a direct 
by‑product of ATP production in mitochondria (van 
Hameren et al., 2019), we may speculate that oxidative 
stress contributed to the electro‑mechanical defects in‑
duced by olanzapine.
Increased fatty acid oxidation and/or lipotoxic‑
ity in the heart inhibit glucose uptake and metabolism 
(D’Souza et al., 2016; Schulze et al., 2016). Several stud‑
ies suggest that glycolytically derived ATP is crucial for 
maintenance of the cellular ion homeostasis (Van Emous 
et al., 2001; Weiss & Maslov, 2004; Xu et al., 1995). 
Since cytosolic malonyl‑CoA levels reciprocally regulate 
fatty acid and pyruvate oxidation (Stanley et al., 1997), 
we may speculate that the lower activity of ACC may 
also be associated with lower activity of pyruvate de‑
hydrogenase (PDH) and a related electrical dysfunction 
(Rozanski & Xu, 2002; Runnman et al., 1990; Stanley et 
al., 1997). In addition, accumulation of toxic lipid spe‑
cies has been linked with inhibition of Akt signalling, as 
well as disturbed AMPK activity (Schulze et al., 2016). In 
our study, acute administration of olanzapine appeared 
to lower phosphorylation of Akt and its downstream tar‑
get AS160, a key regulator of GLUT4 trafficking. Simi‑
larly, phosphorylation of GSK3β, regulating the glycogen 
synthesis, appeared to be decreased in olanzapine‑treat‑
ed hearts, which is in line with depressed Akt/GSK3β 
phosphorylation reported after olanzapine administra‑
tion in the rat skeletal muscle and liver (Engl et al., 2005; 
Mondelli et al., 2013). Moreover, a recent report provid‑
ed a direct link between AS160 phosphorylation levels 
and impaired electrical activity of the heart (Quan et al., 
2015).
Cardiac energy requirements are extremely high in 
order to meet demands for contractile function, as well 
as maintenance of the ion gradients. It is important to 
note that cardiac ATP levels depend on both, the rates 
of production and utilization. Since we observed higher 
ATP levels in association with depressed cardiac func‑
tion, we may speculate that lower utilization of ATP was 
responsible for this effect of olanzapine. Along different 
lines, both inhibition and augmentation of KATP channel 
activity have been reported after treatment with antipsy‑
chotics (Kinoshita et al., 2006; Yang et al., 2004). These 
channels are closed under physiological conditions and 
tend to open with metabolic stress in order to save ener‑
gy. Previous studies demonstrated that blockage of KATP 
channels was mediated by serotonin and histamine ago‑
nists (Bonev & Nelson, 1996; Kleppisch & Nelson, 1995; 
Yang et al., 2004). Given that olanzapine is a serotonin 
and histamine antagonist, it is possible that olanzapine 
promoted KATP channel opening. In addition, intracellular 
accumulation of fatty acids triggers the opening of KATP 
channels (Liu et al., 2001), however KATP activators fail 
to shorten the prolonged QT interval mediated by the 
hERG channel blockers (Testai et al., 2010). Based on 
these points, we may speculate that opening of the KATP 
channels may contribute to the observed elevation of 
cardiac ATP content.
In conclusion, acute olanzapine administration led to 
impaired electrical activity, and reduced contractile func‑
tion and coronary flow in the isolated rat heart. Our data 
support the concept that olanzapine stimulates fatty acid 
oxidation via phosphorylation and inactivation of ACC. 
Although the contractile function was reduced in olan‑
zapine‑treated hearts, cardiac ATP content was elevated. 
The antagonistic action of olanzapine on H1 receptors is 
one mechanism that may contribute to its metabolic and 
contractile effects in the heart. It should, however, be 
highlighted that further studies, particularly chronic and 
in vivo experiments, are needed to confirm this hypoth‑
esis.
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